Published in Clin Med Res on August 04, 2011
Amphotericin B: 30 years of clinical experience. Rev Infect Dis (1990) 5.82
Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs (1990) 2.52
Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis (2008) 2.35
Blastomycosis. Infect Dis Clin North Am (2003) 2.04
Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis (1998) 1.91
Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis (2010) 1.16
Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1997) 0.97
Successful treatment of cerebral blastomycosis with voriconazole. Clin Infect Dis (2005) 0.89
Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole. Pediatr Infect Dis J (2006) 0.89
Amphotericin B lipid complex for the treatment of recurrent blastomycosis of the brain in a patient previously treated with itraconazole. South Med J (2001) 0.82
Case report: treatment of blastomycosis with fluconazole. Am J Med Sci (1992) 0.82
Favourable outcome of blastomycosis of the brain stem with fluconazole and flucytosine treatment. Ann Med (1992) 0.80
Antibiotic treatment duration and long-term outcomes of patients with early lyme disease from a lyme disease-hyperendemic area. Clin Infect Dis (2010) 2.36
Use of optical mapping to sort uropathogenic Escherichia coli strains into distinct subgroups. Microbiology (2010) 1.21
Milkers' nodules complicated by erythema multiforme and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Clin Infect Dis (2005) 1.10
A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr (2005) 1.10
Reassessment of a midwestern Lyme disease focus for Borrelia burgdorferi and the human granulocytic ehrlichiosis agent. J Clin Microbiol (2002) 1.06
Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice. Clin Diagn Lab Immunol (2002) 0.99
Escherichia coli pyomyositis in an immunocompromised host. WMJ (2011) 0.98
High prevalence of genital mycoplasmas among sexually active young adults with urethritis or cervicitis symptoms in La Crosse, Wisconsin. J Clin Microbiol (2004) 0.93
Tularemia, lawn mowers, and rabbits' nests. J Clin Microbiol (2005) 0.88
The effect of residual osteomyelitis at the resection margin in patients with surgically treated diabetic foot infection. J Foot Ankle Surg (2011) 0.79
The differential diagnosis of pulmonary blastomycosis using case vignettes: a Wisconsin Network for Health Research (WiNHR) study. WMJ (2011) 0.77
HIV testing and privacy laws. Clin Infect Dis (2005) 0.75
Chronic granulomatous disease, catalase, and Actinomyces. Clin Infect Dis (2010) 0.75
Adolescent presentation of x-linked lymphoproliferative disease. Ann Allergy Asthma Immunol (2008) 0.75
Antibiotic resistance: unnatural selection in the office and on the farm. WMJ (2002) 0.75
Art supports new plague science. Clin Infect Dis (2009) 0.75
Blastomycosis diagnosed in a nonhyperendemic area. WMJ (2014) 0.75
Management of neutropenic fever during a transition from traditional hematology/oncology service to hospitalist care. WMJ (2014) 0.75